Protective Effect of Galantamine against Doxorubicin-Induced Neurotoxicity
Brain Sciences · 20.06.2023 · 13 (6) · 971
DOI: 10.3390/brainsci13060971 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain Sciences, online erschienen am 20.06.2023. Verfasst von Rawan S Alsikhan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraydah 51452, Saudi Arabia. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and aims: Doxorubicin (DOX) causes cognitive impairment (chemobrain) in patients with cancer. While DOX damages the cholinergic system, few studies have focused on the protective effects of cholinergic function on chemobrain. The acetylcholinesterase inhibitor galantamine (GAL) demonstrates neuroprotective properties. We investigated the mechanisms associated with DOX-induced cognitive impairments and the potential protective role of GAL in preventing chemobrain. Main methods: Female Wistar rats were divided into control, DOX, GAL, and DOX + GAL groups. The rats in the DOX group were administered DOX (5 mg/kg intraperitoneally twice weekly for two weeks), while those in the GAL group were orally administered GAL (2.5 mg/kg) via oral gavage once daily for 15 days. The combination group (DOX + GAL) received GAL (once daily) and DOX (two times per week) concurrently. The body weights and survival rates were monitored daily. The animals were subjected to behavioral tests to assess the memory function followed by the biochemical estimation of inflammatory markers, including tumor necrosis factor-α (TNF-α), interleukine-1β (IL-1β), and interleukine-6 (IL-6) in rat brain tissue and RT-qPCR. Key findings: DOX caused a reduction in the body weight and survival rate, which was alleviated by GAL concomitant treatment with DOX (DOX + GAL). These groups had reduced body weights and survival rates. DOX-treated animals exhibited an impairment of short-term spatial working memory, manifested as a behavioral alteration in the Y-maze test, the novel object recognition (NOR) test, and the elevated plus-maze (EPM) test. Concurrent treatment with GAL (DOX + GAL) showed improved memory function, as evidenced by an increase in the number of entries and time spent in the novel arm, the time spent exploring the novel object, and the transfer latency in the Y-maze, NOR test, and EPM test, respectively. These findings were also supported by biochemical observations showing the reversal of DOX-induced changes in IL-1β, IL-6, and TNF-α, as well as their relative expression of mRNA in brain tissue following concurrent GAL treatment. Conclusion: GAL appeared to be a neuroprotective agent against neuroinflammation caused by DOX by reducing inflammatory markers in the brain.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraydah 51452, Saudi Arabia.
- Department of Pharmacology and Toxicology, Unaizah College of Pharmacy, Qassim University, Unaizah 51911, Saudi Arabia.
- Department of Biology, College of Science, Qassim University, Buraydah 51452, Saudi Arabia.
ORCID-Profile: Rawan S Alsikhan, Ibtesam S Almami, Ahmad H Alhowail
Zitieren
APA
Alsikhan, R. S., Aldubayan, M. A., Almami, I. S., & Alhowail, A. H. (2023). Protective Effect of Galantamine against Doxorubicin-Induced Neurotoxicity. Brain Sciences, 13(6), 971. https://doi.org/10.3390/brainsci13060971
Vancouver
Alsikhan RS, Aldubayan MA, Almami IS, Alhowail AH. Protective Effect of Galantamine against Doxorubicin-Induced Neurotoxicity. Brain Sciences. 2023;13(6):971. doi:10.3390/brainsci13060971
BibTeX
@article{Alsikhan2023,
author = {Alsikhan, Rawan S and Aldubayan, Maha A and Almami, Ibtesam S and Alhowail, Ahmad H},
title = {Protective Effect of Galantamine against Doxorubicin-Induced Neurotoxicity},
journal = {Brain Sciences},
year = {2023},
volume = {13},
number = {6},
pages = {971},
doi = {10.3390/brainsci13060971}
}
EUVIMED